2021 | |
| Andreas Venizelos | «Mutational characterisation of cancers». |
2020 | |
| Deepak B Poduval | «Studies on sequencing analyses of genetic and epigenetics features in melanoma and breast cancer». |
2018 | |
| Synnøve Yndestad | «The role of PTEN, PI3K-Akt-mTOR signaling and pseudogene PTENP1 in breast cancer». |
| Einar Elvbakken Birkeland | «Genomic evolution and therapy resistance in melanoma and breast cancer». |
2017 | |
| Johanna Huun | «Response to doxorubicin in breast cancer cells; The role of p53-, MDM2- and pRb-variants». |
2016 | |
| Inger Marie Løes | «Genetic heterogeneity in liver metastases from colorectal cancer». |
2013 | |
| Liv Gansmo | «MDM2 polymorphisms: The impact of four promoter variants on cancer risk». |
2012 | |
| Anne Hege Straume | «A genetic perspective on estrogen metabolism in cancer: The potential role of alterations affecting CYP19, 17β-HSD2 and 17β-HSD7». |
2010 | |
| Elisabet Ognedal Berge | «Chemotherapy Resistance in Breast Cancer: The potential role of Chk2 splice variants and RB1 alterations». |
| Christian Busch | «Genetic biomarkers as prognostic and predictive factors in metastatic malignant melanoma». |
2009 | |
| Ranjan Chrisanthar | «Resistance to Chemotherapy in Breast Cancer: Potential role of p21B, p27 and the p53 apoptotic pathway». |
2007 | |
| Stian Knappskog | «Germline Genetic Alterations Affecting CDKN2A, MDM2 and CDKN1A in Melanoma and Breast Cancer Patients». |
| Vidar Staalesen | «Chemoresistance in Breast Cancer: Alterations in the p53 Pathway and Integrity of the DNA Damage Response». |
2002 | |
| Jürgen Geisler | «Aromatase Inhibition in Postmenopausal Breast Cancer Patients». |
2001 | |
| Svein Inge Helle | «The Insulin-like Growth Factor System in Breast Cancer - Effects of Endocrine Treatment and Alterations in Tumor Burden». |
